Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021
Open Access
- 12 May 2022
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (19), 2100746-50
- https://doi.org/10.2807/1560-7917.es.2022.27.19.2100746
Abstract
Background Mycoplasma pneumoniae respiratory infections are transmitted by aerosol and droplets in close contact. Aim We investigated global M. pneumoniae incidence after implementation of non-pharmaceutical interventions (NPIs) against COVID-19 in March 2020. Methods We surveyed M. pneumoniae detections from laboratories and surveillance systems (national or regional) across the world from 1 April 2020 to 31 March 2021 and compared them with cases from corresponding months between 2017 and 2020. Macrolide-resistant M. pneumoniae (MRMp) data were collected from 1 April 2017 to 31 March 2021. Results Thirty-seven sites from 21 countries in Europe, Asia, America and Oceania submitted valid datasets (631,104 tests). Among the 30,617 M. pneumoniae detections, 62.39% were based on direct test methods (predominantly PCR), 34.24% on a combination of PCR and serology (no distinction between methods) and 3.37% on serology alone (only IgM considered). In all countries, M. pneumoniae incidence by direct test methods declined significantly after implementation of NPIs with a mean of 1.69% (SD ± 3.30) compared with 8.61% (SD ± 10.62) in previous years (p < 0.01). Detection rates decreased with direct but not with indirect test methods (serology) (–93.51% vs + 18.08%; p < 0.01). Direct detections remained low worldwide throughout April 2020 to March 2021 despite widely differing lockdown or school closure periods. Seven sites (Europe, Asia and America) reported MRMp detections in one of 22 investigated cases in April 2020 to March 2021 and 176 of 762 (23.10%) in previous years (p = 0.04). Conclusions This comprehensive collection of M. pneumoniae detections worldwide shows correlation between COVID-19 NPIs and significantly reduced detection numbers.Keywords
This publication has 55 references indexed in Scilit:
- Therapeutic Efficacy of Macrolides, Minocycline, and Tosufloxacin against Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Pediatric PatientsAntimicrobial Agents and Chemotherapy, 2013
- Reporting Guidelines for Survey Research: An Analysis of Published Guidance and Reporting PracticesPLoS Medicine, 2011
- Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencingJournal of Microbiological Methods, 2010
- Evaluation of Five Commercial Real-Time PCR Assays for Detection of Mycoplasma pneumoniae in Respiratory Tract SpecimensJournal of Clinical Microbiology, 2009
- Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysisJournal of Antimicrobial Chemotherapy, 2009
- Aetiological diagnosis of community acquired pneumonia: Utility of rapid microbiological methods with respect to disease severityScandinavian Journal of Infectious Diseases, 2008
- Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infectionClinical Microbiology & Infection, 2006
- Mycoplasma pneumoniaeand Its Role as a Human PathogenClinical Microbiology Reviews, 2004
- Results of Molecular Detection ofMycoplasma pneumoniaeamong Patients with Acute Respiratory Infection and in Their Household Contacts Reveals Children as Human ReservoirsThe Journal of Infectious Diseases, 2001
- Postal research: too many problems?Sexually Transmitted Infections, 2000